Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.

Bluethmann SM, Murphy CC, Tiro JA, Mollica MA, Vernon SW, Bartholomew LK.

Oncol Nurs Forum. 2017 May 1;44(3):E101-E110. doi: 10.1188/17.ONF.E101-E110.

2.

Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review.

Harris HR, Terry KL.

Fertil Res Pract. 2016 Dec 5;2:14. doi: 10.1186/s40738-016-0029-2. eCollection 2016. Review.

3.

Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.

Kanomata N, Matsuura S, Nomura T, Kurebayashi J, Mori T, Kitawaki J, Moriya T.

PLoS One. 2017 May 10;12(5):e0177439. doi: 10.1371/journal.pone.0177439. eCollection 2017. Erratum in: PLoS One. 2017 Aug 8;12 (8):e0183202.

4.

Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.

Karmakar M, Pinto SL, Jordan TR, Mohamed I, Holiday-Goodman M.

Breast Cancer (Auckl). 2017 Mar 2;11:1178223417694520. doi: 10.1177/1178223417694520. eCollection 2017.

5.

Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.

Timmermans-Sprang EPM, Gracanin A, Mol JA.

Front Vet Sci. 2017 Apr 13;4:53. doi: 10.3389/fvets.2017.00053. eCollection 2017. Review.

6.

Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.

Henry NL, Speth K, Lintermans A, Kidwell KM, Carlson R, Hayes DF, Neven P.

Clin Breast Cancer. 2017 Aug;17(5):350-355.e4. doi: 10.1016/j.clbc.2017.03.002. Epub 2017 Mar 11.

PMID:
28365336
7.

Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer.

Kwan ML, Roh JM, Laurent CA, Lee J, Tang L, Hershman D, Kushi LH, Yao S.

Cancer Causes Control. 2017 Jun;28(6):557-562. doi: 10.1007/s10552-017-0888-9. Epub 2017 Mar 27.

PMID:
28349440
8.

A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.

Abushwereb HS, Elhabash M, Elhamshari S, Eshaefi H.

Clin Cases Miner Bone Metab. 2016 Sep-Dec;13(3):186-189. doi: 10.11138/ccmbm/2016.13.3.186. Epub 2017 Feb 10.

9.

Breast Cancer Profile among Patients with a History of Chemoprevention.

Schnabel FR, Pivo S, Chun J, Schwartz S, Refinetti AP, Axelrod D, Guth A.

Int J Breast Cancer. 2016;2016:9216375. doi: 10.1155/2016/9216375. Epub 2016 Dec 18.

10.

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.

Oncotarget. 2017 Jan 31;8(5):8406-8419. doi: 10.18632/oncotarget.14139.

11.

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP.

Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. Review.

PMID:
27988492
12.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

PMID:
27943008
13.

The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.

Farias AJ, Hansen RN, Zeliadt SB, Ornelas IJ, Li CI, Thompson B.

Am J Clin Oncol. 2016 Nov 23. [Epub ahead of print]

PMID:
27893470
14.

Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).

Agrawal S, Banswal L, Saha A, Arun I, Datta SS, Chatterjee S, Ahmed R.

Indian J Surg Oncol. 2016 Dec;7(4):397-406. Epub 2016 Apr 23.

PMID:
27872526
15.

Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.

Monroy-Cisneros K, Esparza-Romero J, Valencia ME, Guevara-Torres AG, Méndez-Estrada RO, Anduro-Corona I, Astiazarán-García H.

BMC Cancer. 2016 Nov 8;16(1):860.

16.

"Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.

Brauer ER, Ganz PA, Pieters HC.

J Oncol Pract. 2016 Dec;12(12):e991-e1000. Epub 2016 Sep 30.

17.

Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells.

Radde BN, Ivanova MM, Mai HX, Alizadeh-Rad N, Piell K, Van Hoose P, Cole MP, Muluhngwi P, Kalbfleisch TS, Rouchka EC, Hill BG, Klinge CM.

Exp Cell Res. 2016 Sep 10;347(1):222-31. doi: 10.1016/j.yexcr.2016.08.006. Epub 2016 Aug 8.

PMID:
27515002
18.

Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.

Baum T, Karampinos DC, Seifert-Klauss V, Pencheva TD, Jungmann PM, Rummeny EJ, Müller D, Bauer JS.

Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):29-32. doi: 10.11138/ccmbm/2016.13.1.029. Epub 2016 May 11.

19.

Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.

Wells KJ, Pan TM, Vázquez-Otero C, Ung D, Ustjanauskas AE, Muñoz D, Laronga C, Roetzheim RG, Goldenstein M, Carrizosa C, Nuhaily S, Johnson K, Norton M, Sims E, Quinn GP.

Support Care Cancer. 2016 Oct;24(10):4123-30. doi: 10.1007/s00520-016-3229-8. Epub 2016 May 5.

PMID:
27146492
20.

Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.

Felder TM, Do DP, Lu ZK, Lal LS, Heiney SP, Bennett CL.

Breast Cancer Res Treat. 2016 May;157(1):193-200. doi: 10.1007/s10549-016-3803-2. Epub 2016 Apr 27.

Supplemental Content

Support Center